These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 36238357)

  • 1. Study on the method to avoid infusion-site adverse events following chemotherapeutic treatment with epirubicin and fosaprepitant using immortalized human umbilical vein endothelial cells.
    Yamasaki M; Oda K; Ichinose T; Mizuguchi M; Tominaga S; Omoda K; Mori N; Maeda Y; Nishida T; Murakami T
    Oncol Lett; 2022 Nov; 24(5):386. PubMed ID: 36238357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Study on the infusion-site adverse events and vascular distribution of epirubicin in chemotherapy with epirubicin and fosaprepitant.
    Yamasaki M; Kimura R; Mayahara S; Maeda Y; Takahashi M; Nishida T; Oda K; Murakami T
    Mol Clin Oncol; 2019 Jul; 11(1):43-49. PubMed ID: 31289676
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti-emetic treatment with aprepitant and fosaprepitant: A retrospective comparison.
    Tsuda T; Kyomori C; Mizukami T; Taniyama T; Izawa N; Horie Y; Hirakawa M; Ogura T; Nakajima TE; Tsugawa K; Boku N
    Mol Clin Oncol; 2016 Apr; 4(4):603-606. PubMed ID: 27073673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of a Single 150-mg Intravenous Infusion of Fosaprepitant: Effects of Concentration and Infusion Time in Healthy Japanese Men.
    Azuma J; Fukase H
    Clin Pharmacol Drug Dev; 2013 Oct; 2(4):394-9. PubMed ID: 27121944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Updated report on incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Chau E; Lundberg J; Phillips G; Berger M; Wesolowski R
    J Oncol Pharm Pract; 2019 Jul; 25(5):1053-1057. PubMed ID: 29651918
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hypersensitivity and infusion-site adverse events with intravenous fosaprepitant after anthracycline-containing chemotherapy: a retrospective study.
    Boccia R; Geller RB; Clendeninn N; Ottoboni T
    Future Oncol; 2019 Jan; 15(3):297-303. PubMed ID: 30301373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential impact of fosaprepitant on infusion site adverse events between cisplatin- and anthracycline-based chemotherapy regimens.
    Fujii T; Nishimura N; Urayama KY; Kanai H; Ishimaru H; Kawano J; Takahashi O; Yamauchi H; Yamauchi T
    Anticancer Res; 2015 Jan; 35(1):379-83. PubMed ID: 25550575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of venous pain and phlebitis caused by epirubicin hydrochloride.
    Sugimoto M; Matsui M; Harada M; Yamauchi Y; Moriyama N; Andou K; Yamamoto M; Yamaoka H; Ono C; Ishikawa M; Kamo N; Ikeda T; Yamaoka K
    Gan To Kagaku Ryoho; 2009 Jun; 36(6):969-74. PubMed ID: 19542717
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined effect of epirubicin and lymphokine-activated killer cells on the resistant human breast cancer cells.
    Ozkan A; Ayhan A; Fiskin K
    Cell Biol Toxicol; 2004 Sep; 20(5):261-71. PubMed ID: 15685929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dose escalation study of epirubicin and docetaxel in patients with advanced or recurrent breast cancer.
    Ichinose I; Hamada Y; Mitsuyama S; Ishikawa E; Ikeda T; Kobayashi S; Horikoshi N; Tamura K
    Chemotherapy; 2008; 54(5):379-85. PubMed ID: 18758179
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant.
    Lundberg JD; Crawford BS; Phillips G; Berger MJ; Wesolowski R
    Support Care Cancer; 2014 Jun; 22(6):1461-6. PubMed ID: 24402412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Double targeting and aptamer-assisted controlled release delivery of epirubicin to cancer cells by aptamers-based dendrimer in vitro and in vivo.
    Taghdisi SM; Danesh NM; Ramezani M; Lavaee P; Jalalian SH; Robati RY; Abnous K
    Eur J Pharm Biopharm; 2016 May; 102():152-8. PubMed ID: 26987703
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epirubicin loaded super paramagnetic iron oxide nanoparticle-aptamer bioconjugate for combined colon cancer therapy and imaging in vivo.
    Jalalian SH; Taghdisi SM; Shahidi Hamedani N; Kalat SA; Lavaee P; Zandkarimi M; Ghows N; Jaafari MR; Naghibi S; Danesh NM; Ramezani M; Abnous K
    Eur J Pharm Sci; 2013 Oct; 50(2):191-7. PubMed ID: 23835028
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Optimization of epirubicin nanoparticles using experimental design for enhanced intravesical drug delivery.
    Chang LC; Wu SC; Tsai JW; Yu TJ; Tsai TR
    Int J Pharm; 2009 Jul; 376(1-2):195-203. PubMed ID: 19439169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Schedule-dependent effects of kappa-selenocarrageenan in combination with epirubicin on hepatocellular carcinoma.
    Ji YB; Ling N; Zhou XJ; Mao YX; Li WL; Chen N
    Asian Pac J Cancer Prev; 2014; 15(8):3651-7. PubMed ID: 24870773
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
    Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
    Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients.
    Sato Y; Kondo M; Inagaki A; Komatsu H; Okada C; Naruse K; Sahashi T; Kuroda J; Ogura H; Uegaki S; Yoshida T; Mori Y; Sawada H; Watanabe S; Sugiura H; Endo Y; Yoshimoto N; Toyama T; Iida S; Yamada K; Kimura K; Wakita A
    J Cancer; 2014; 5(5):390-7. PubMed ID: 24799957
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation.
    Ottoboni T; Keller MR; Cravets M; Clendeninn N; Quart B
    Drug Des Devel Ther; 2018; 12():429-435. PubMed ID: 29535504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences in Transport Characteristics and Cytotoxicity of Epirubicin and Doxorubicin in HepG2 and A549 Cells.
    Nagai K; Fukuno S; Shiota M; Tamura M; Yabumoto S; Konishi H
    Anticancer Res; 2021 Dec; 41(12):6105-6112. PubMed ID: 34848465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Best Practice Approach to Successful Conversion of Fosaprepitant to Aprepitant IV in a Large Multisite Community Oncology Infusion Center: A Retrospective Analysis.
    Burns D; Kula J; Marshall S; Ashworth E; Ornelas M
    Adv Ther; 2020 Jul; 37(7):3265-3277. PubMed ID: 32447650
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.